[go: up one dir, main page]

ES2140489T3 - Receptor de interferona soluble, su preparacion y su uso. - Google Patents

Receptor de interferona soluble, su preparacion y su uso.

Info

Publication number
ES2140489T3
ES2140489T3 ES94116559T ES94116559T ES2140489T3 ES 2140489 T3 ES2140489 T3 ES 2140489T3 ES 94116559 T ES94116559 T ES 94116559T ES 94116559 T ES94116559 T ES 94116559T ES 2140489 T3 ES2140489 T3 ES 2140489T3
Authority
ES
Spain
Prior art keywords
interferone
soluble
receiver
preparation
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94116559T
Other languages
English (en)
Inventor
Carolina Abramovich
Edward Ratovitski
Michel Revel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2140489T3 publication Critical patent/ES2140489T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)

Abstract

SE PROPORCIONAN NUEVAS FORMAS DE AL -RECEPTORES DE INTERFERONA. PUEDEN SER PREPARADAS RECOMBINANTEMENTE Y PUEDEN SER UTILIZADAS EN DIAGNOSIS Y TERAPIA.
ES94116559T 1993-10-24 1994-10-20 Receptor de interferona soluble, su preparacion y su uso. Expired - Lifetime ES2140489T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10737893A IL107378A (en) 1993-10-24 1993-10-24 SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE

Publications (1)

Publication Number Publication Date
ES2140489T3 true ES2140489T3 (es) 2000-03-01

Family

ID=11065371

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94116559T Expired - Lifetime ES2140489T3 (es) 1993-10-24 1994-10-20 Receptor de interferona soluble, su preparacion y su uso.

Country Status (13)

Country Link
US (1) US5643749A (es)
EP (1) EP0679717B1 (es)
JP (3) JPH07236488A (es)
AT (1) ATE183774T1 (es)
AU (1) AU684103B2 (es)
CA (1) CA2134030C (es)
DE (1) DE69420251T2 (es)
DK (1) DK0679717T3 (es)
ES (1) ES2140489T3 (es)
GR (1) GR3031354T3 (es)
IL (1) IL107378A (es)
SI (1) SI0679717T1 (es)
ZA (1) ZA948345B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2585487A1 (fr) * 1991-04-17 1992-10-29 Medarex Inc. Polypeptides hydrosolubles ayant une haute affinite pour les interferons .alpha. et .beta.
US5780027A (en) * 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
WO1998008099A1 (en) * 1996-08-19 1998-02-26 SHAKER, Ghassan, I. Use of molt4 cd69 expression to determine the presence and activity of interferon inhibitors
US20020119129A1 (en) 1997-01-15 2002-08-29 Yeda Research And Development Co. Ltd. Novel IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons
SI1019500T1 (sl) * 1997-01-15 2007-02-28 Yeda Res & Dev Proteini, ki vezejo receptor 1 za ifn, dna, ki jih kodira, in postopki za regulacijo celicnega odziva na interferone
UA75560C2 (en) 1997-01-15 2006-05-15 Yeda Res & Dev New interferon receptor 1-binding proteins, dna, coding them and methods for modulation of cells reaction to interferons
ATE218362T1 (de) * 1997-12-19 2002-06-15 Applied Research Systems Ifnnar/ifn komplex
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
UA74557C2 (en) * 1999-09-03 2006-01-16 Applied Research Systems A method for producing a heterologous secreted protein from chinese hamster ovaries cells grown on microcarriers
IL147414A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
MX2007016343A (es) * 2005-06-22 2008-03-05 Genentech Inc Metodos y composiciones para ser blanco en ifnar2.
WO2013003475A1 (en) 2011-06-27 2013-01-03 Cellscript, Inc. Inhibition of innate immune response
ES2470816B1 (es) 2012-11-22 2015-04-01 Servicio Andaluz De Salud Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple
WO2018005954A2 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0393502T3 (da) * 1989-04-19 1996-03-04 Hoffmann La Roche Opløselige interferon-gamma-receptorer og fremgangsmåder til fremstilling heraf
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
CA2585487A1 (fr) * 1991-04-17 1992-10-29 Medarex Inc. Polypeptides hydrosolubles ayant une haute affinite pour les interferons .alpha. et .beta.
IL106591A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
US5643749A (en) 1997-07-01
DE69420251T2 (de) 2000-05-11
IL107378A0 (en) 1994-01-25
SI0679717T1 (en) 1999-12-31
AU7597794A (en) 1995-05-11
CA2134030A1 (en) 1995-04-25
DK0679717T3 (da) 2000-03-13
EP0679717A2 (en) 1995-11-02
JP2007097593A (ja) 2007-04-19
GR3031354T3 (en) 2000-01-31
ZA948345B (en) 1995-07-17
EP0679717B1 (en) 1999-08-25
EP0679717A3 (en) 1997-04-23
ATE183774T1 (de) 1999-09-15
JP2005130865A (ja) 2005-05-26
AU684103B2 (en) 1997-12-04
DE69420251D1 (de) 1999-09-30
CA2134030C (en) 2010-06-29
JPH07236488A (ja) 1995-09-12
IL107378A (en) 2005-05-17

Similar Documents

Publication Publication Date Title
AU623512B2 (en) Phenyl pyrimidone derivatives, processes for their preparation, and their use therapeutic agents
ES2140489T3 (es) Receptor de interferona soluble, su preparacion y su uso.
FI905770L (fi) Uusia isoindolonijohdannaisia niiden valmistus ja käyttö
BR9708400A (pt) Composição sua preparação e uso
FI940904L (fi) Oksatsolidiinidionijohdannaiset, niiden valmistus ja käyttö
IL96458A0 (en) Isoxazolines,their preparation,and their use as plantprotecting agents
FI971953L (fi) Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6-aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit
NO933434D0 (no) Piperidinderivater, deres fremstilling og anvendelse
FI943512L (fi) Ihmisen seerumialbumiini, valmistus ja käyttö
FI944600L (fi) Imidatsol-4-yylipiperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
AU8487191A (en) 2-aminopyrimidine-4-caroxamide derivatives, their preparation and their use in therapy
GB2191498B (en) Pyrroline derivatives, their preparation and their use as colouring agents
EE9900218A (et) 1,4-diasabitsüklo[2.2.2]okt-2-üülmetüülbensoaadi derivaadid, nende valmistamine ja kasutamine raviks
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
FI961977L (fi) N-substituoidut atsabisykloalkaanijohdannaiset, niiden valmistus ja käyttö
NO933435D0 (no) Piperidinderivater, deres fremstilling og anvendelse
AU618865B2 (en) Adenosin derivatives, their preparation and use
EE200000207A (et) 8-asabitsüklo[3.2.1]oktaan-3-metaanamiini derivaadid, nende valmistamine ja terapeutiline kasutamine
FI970750L (fi) Indoli-2,3-dioni-3-oksimijohdannaisia, niiden valmistus ja käyttö
HUP9902883A3 (en) Bis/acridinecarboxamide/ and bis/phenazinecarboxamide/ derivatives as antitumour agents, preparation and use thereof
ZA903340B (en) 5-substituted 3-arylisoxazole derivatives,their preparation and their use as pesticides
FI971528L (fi) Pyrrolyylitetrahydrobentsokinoksaliinidionit, niiden valmistus ja käyttö glutamaattireseptoriantagonisteina
FI941214L (fi) Bentsimidatsolin johdannaisia, niiden valmistus ja käyttö
DK253888A (da) Tricycliske imidazoloner, ders fremstilling og anvendelse
BR9106372A (pt) Derivados 1,5-benzotiazepinona,suas preparacoes e uso farmaceutico

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 649903

Country of ref document: ES